Tipifarnib (ZARNESTRA™) in previously untreated poor-risk AML of the elderly:: Updated results of a multicenter phase 2 trial.

被引：18

作者：

Lancet, JE

Gotlib, J

Gojo, I

Feldman, EJ

Morris, L

Thibault, A

Liesveld, JL

Greer, J

Dugan, K

Raponi, M

Wright, JJ

Greenberg, PL

Karp, JE

机构：

[1] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA

[2] Stanford Univ, Dept Hematol, Stanford, CA USA

[3] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD USA

[4] Cornell Univ, New York, NY USA

[5] Blood & Marrow Transplant Grp, Atlanta, GA USA

[6] Johnson & Jonson PRD, Raritan, NJ USA

[7] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[8] Veridex LLC, San Diego, CA USA

[9] NCI, Bethesda, MD USA

来源：

关键词：

D O I：

10.1182/blood.V104.11.874.874

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

874

引用

页码：249A / 249A

页数：1